Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EA2165
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
- NCT03233711 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on EA2165 (nivolumab in Anal Basaloid Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA2165 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Colonoscopy; Computed Tomography; Digital Rectal Examination; High Resolution Anoscopy; Magnetic Resonance Imaging; Nivolumab; Patient Observation; Proctoscopy; Sigmoidoscopy; X-Ray Imaging
- Arms
- Arm A (nivolumab) · Experimental
- Arm B (clinical observation) · Other
- Enrollment
- 344 (estimated)
- Primary outcomes
- Disease free survival
- Sponsor
- National Cancer Institute (NCI) with Canadian Cancer Trials Group
- Start
- Jul 5, 2018
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03233711 · updated Oct 26, 2026